


The *IFITM5* mutation in osteogenesis imperfecta type V is associated with an ERK/SOX9-dependent osteoprogenitor differentiation defect

Ronit Marom, ... , Jason D. Heaney, Brendan H. Lee

J Clin Invest. 2024. <https://doi.org/10.1172/JCI170369>.

Research In-Press Preview Bone biology Genetics

Graphical abstract



Find the latest version:

<https://jci.me/170369/pdf>



The *IFITM5* mutation in osteogenesis imperfecta type V is associated with an ERK/SOX9-dependent osteoprogenitor differentiation defect

Ronit Marom^{1,2*}, I-Wen Song¹, Emily C. Busse^{1,3}, Megan E. Washington¹, Ava S. Berrier¹, Vittoria C. Rossi^{1,2}, Laura Ortinau¹, Youngjae Jeong¹, Ming-Ming Jiang¹, Brian C. Dawson¹, Mary Adeyeye¹, Carolina Leynes¹, Caressa D. Lietman^{1†}, Bridget M. Stroup¹, Dominyka Batkovskytė^{1‡}, Mahim Jain¹, Yuqing Chen¹, Racel Cela¹, Alexis Castellon¹, Alyssa A. Tran¹, Isabelle Lorenzo¹, D. Nicole Meyers⁴, Shixia Huang⁵, Alicia Turner^{1,2}, Vinitha Shenava⁶, Maegen Wallace^{7§}, Eric Orwoll⁸, Dongsu Park¹, Catherine G. Ambrose⁴, Sandesh C.S. Nagamani^{1,2}, Jason D. Heaney¹ and Brendan H. Lee^{1,2*}

Affiliations:

¹Department of Molecular and Human Genetics, Baylor College of Medicine, Houston TX, 77030 USA

²Texas Children's Hospital, Houston TX, 77030 USA

³Medical Scientist Training Program, Baylor College of Medicine, Houston TX, 77030 USA

⁴Department of Orthopaedic Surgery, McGovern Medical School at UT Health, Houston TX, 77030 USA

⁵Department of Molecular and Cellular Biology, and Department of Education, Innovation, and Technology, Advanced Technology Cores, Baylor College of Medicine, Houston TX, 77030 USA

⁶Department of Orthopedic Surgery, Baylor College of Medicine, Houston TX, 77030 USA

⁷Orthopaedic Surgery, University of Nebraska Medical Center, Children's Hospital and Medical Center, Omaha NE, 68114 USA

⁸Department of Medicine, Bone and Mineral Unit, Oregon Health & Science University, Portland OR, 97239 USA

† CDL present affiliation: Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville TN, USA

‡ DB present affiliation: Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, 17177 Sweden

§ MW present affiliation: Phoenix Children's Hospital, University of Arizona, Phoenix AZ, USA

***To whom correspondence should be addressed:**

Brendan Lee, M.D., Ph.D.
Department of Molecular and Human Genetics
Baylor College of Medicine
One Baylor Plaza, Room R814

Houston, TX 77030

Fax number: 713-798-5168

Telephone number: 713-798-8853

Email: blee@bcm.edu

Ronit Marom, M.D., Ph.D.

Department of Molecular and Human Genetics

Baylor College of Medicine

One Baylor Plaza, Room R803

Houston, TX 77030

Fax number: 713-798-5168

Telephone number: 713-798-4523

Email: ronit.marom@bcm.edu

The authors have declared that no conflict of interest exists.

ABSTRACT

Osteogenesis imperfecta (OI) type V is the second most common form of OI, distinguished by hyperplastic callus formation and calcification of the interosseous membranes in addition to bone fragility. It is caused by a recurrent, dominant pathogenic variant (c.-14C>T) in *IFITM5*. Here, we generated a conditional *Rosa26* knock-in mouse model to study the mechanistic consequences of the recurrent mutation. Expression of the mutant *Ifitm5* in osteo-chondroprogenitor or chondrogenic cells resulted in low bone mass and growth retardation. Mutant limbs showed impaired endochondral ossification, cartilage overgrowth, and abnormal growth plate architecture. The cartilage phenotype correlates with the pathology reported in OI type V patients. Surprisingly, expression of mutant *Ifitm5* in mature osteoblasts caused no obvious skeletal abnormalities. In contrast, earlier expression in osteo-chondroprogenitors was associated with increase in the skeletal progenitor population within the periosteum. Lineage tracing showed that chondrogenic cells expressing the mutant *Ifitm5* showed decreased differentiation into osteoblastic cells in diaphyseal bone. Moreover, mutant *IFITM5* disrupts early skeletal homeostasis in part by activating ERK signaling and downstream SOX9 protein, and inhibition of these pathways partially rescued the phenotype in mutant animals. These data identify the contribution of a signaling defect altering osteo-chondroprogenitor differentiation as a driver in the pathogenesis of OI type V.

1 INTRODUCTION

2 Osteogenesis imperfecta (OI) is an inherited multi-systemic disorder characterized by low
3 bone mass, recurrent fractures, growth deficiency and skeletal deformities (1-3). Extra-skeletal
4 manifestations may include muscle weakness, dentinogenesis imperfecta, hearing loss, and
5 pulmonary disease (1-3). OI is genetically and phenotypically heterogenous. Most OI (~85%) is
6 caused by pathogenic variants in *COL1A1* or *COL1A2* which encode alpha 1 and alpha 2 chains
7 of type I collagen, respectively, while the remainder are caused by pathogenic variants in genes
8 involved in collagen processing, or in the regulation of bone homeostasis (1, 3, 4). OI type V is
9 the most common type of OI that is not caused by alterations in type I collagen and is estimated
10 to account for up to 9-10 percent of moderate-severe OI (5-7). Clinically, OI type V is
11 characterized by the unique features of hyperplastic callus formation (which can occur with or
12 without a fracture), and calcification of the interosseous membranes, in addition to the bone
13 fragility (8). Notably, all individuals with OI type V have the same autosomal dominant
14 pathogenic variant (c.-14C>T) in *IFITM5* (9-12). This variant resides in the 5' untranslated
15 region (UTR) and introduces a new in-frame start codon, adding 5 amino acid residues at the N
16 terminus of the protein (13). *IFITM5* encodes the interferon inducible transmembrane protein 5
17 (also known as BRIL), a member of the highly conserved IFITM (interferon-induced-
18 transmembrane) family of proteins that are implicated in innate immune response (9-12, 14).
19 Unlike other IFITM proteins that are expressed ubiquitously, *IFITM5* is primarily expressed in
20 skeletal tissues, in osteoblasts (15, 16), chondrocytes (9, 15, 17), and progenitor niches like the
21 groove of Ranvier (9). Studies suggest that it has a role in bone mineralization (15) but does not
22 exhibit anti-viral activity or other function related to the immune system, as observed with other
23 IFITM proteins (18).

1 The molecular consequences of the recurrent (c.-14C>T) OI type V pathogenic variant
2 remain unknown. Expression of the mutant *Ifitm5* allele in transgenic mice overexpressing the
3 mutant protein in bone, and in CRISPR/Cas9 knock-in mouse models, both resulted in a severe
4 OI phenotype with perinatal lethality (19-21). Importantly, overexpression of wild type *Ifitm5*
5 and complete loss-of-function models showed no obvious phenotypes (16, 19). Thus, a
6 *neomorphic* effect in bone has been suggested as the most likely mechanism. However, the
7 cellular and signaling mechanisms by which the mutant IFITM5 drives the skeletal pathology is
8 not understood. Here, we report a conditional *Rosa26* mutant *Ifitm5* knock-in mouse model that
9 is viable and recapitulates the human phenotype, thus facilitating the understanding of the role of
10 the mutant protein in specific stages of osteoblast and chondrocyte differentiation. Findings in
11 this model, supported by studies in the previously reported transgenic *Ifitm5*^{c.-14C>T} mice (19), as
12 well as in zebrafish and *in vitro* cell culture models, point to downstream activation of ERK
13 (Extracellular signal-Regulated Kinase)/MAPK (Mitogen-Activated Protein Kinase) signaling
14 and increased SOX9 protein leading to the abnormal osteo-chondroprogenitor differentiation in
15 OI type V pathogenesis.

RESULTS

Conditional expression of the mutant Ifitm5^{c.-14C>T} allele in limb mesenchyme (Rosa26^{mIfitm5};Prx1-Cre), but not in mature osteoblasts (Rosa26^{mIfitm5};OC-Cre), results in low bone mass.

All mouse models generated to date for OI type V exhibit perinatal lethality. Therefore, we generated a conditional mouse expressing the disease-causing *IFITM5* mutation at specific stages of osteoblast and chondrocyte cell differentiation. We inserted the mutant *Ifitm5^{c.-14C>T}* allele (*mIfitm5*) into the *Rosa26* locus (22) via homologous recombination (**Fig. 1A, B**). To study whether the human OI type V phenotype is recapitulated in this model, we crossed mice that are heterozygous for the *Rosa26* knock-in *mIfitm5* allele (*Rosa26^{mIfitm5/+}*) with: 1) Paired related homeobox 1 (*Prx1-Cre*) transgenic mice that express the Cre-recombinase (*Cre/-*) in mesenchymal precursors of the osteo-chondroprogenitor lineage, and 2) Osteocalcin-Cre (*OC-Cre*) transgenic mice that express the Cre-recombinase (*Cre/-*) in mature osteoblasts. Controls included littermates that expressed only Cre-recombinase (*Cre/-*), that carried only the *Rosa26* knock-in allele (*Rosa26^{mIfitm5/+}*), or that carried neither allele (*Rosa26^{+/+}*). The activation of *Cre* recombinase was validated by PCR using primers spanning the deleted *LoxP* cassette, and by quantitative RT-PCR showing expression of the mutant *Ifitm5* mRNA in bone (**Fig. S1**).

At age 2 months, trabecular bone volume (BV/TV), as measured by micro CT in distal femurs, was significantly reduced in the *Rosa26^{mIfitm5};Prx1-Cre* mice in both males (**Fig. 2A**) and females (**Fig. S2**). Consistent with this finding, trabecular number was decreased and trabecular spacing was increased in *Rosa26^{mIfitm5};Prx1-Cre* mice compared to littermate controls. Cortical thickness was not significantly affected, but histological sections showed immature bone, as is seen in bone histology from a patient with OI type V (**Fig. 2B**), and consistent with previous

reports (8). Interestingly, expression of the mutant *Ifitm5* allele in mature osteoblasts in the *Rosa26^{mlfifm5};OC-Cre* mice did not have an obvious effect on bone mass in mutant mice (*Rosa26^{mlfifm5/+};OC-Cre/-*) compared with controls (**Fig.2C and Fig. S3**). We further studied the effect of mutant *Ifitm5* expression in committed, early-differentiating osteoblasts via the 2.3 kb rat *Col1a1*-Cre promoter (*Rosa26^{mlfifm5};Col1a1-Cre*). In this model, the bone mass in mutant animals was not significantly different than Cre controls (**Fig. S4**). The divergent observations, in *Rosa26^{mlfifm5};OC-Cre* and *Rosa26^{mlfifm5};Col1a1-Cre* vs. *Rosa26^{mlfifm5};Prx1-Cre* mouse models, represent the consequences of distinct temporo-spatial expression of the mutant protein and suggest an early developmental effect in osteo-chondroprogenitors, and that its expression in committed and mature osteoblasts is not a major contributor to the bone phenotype.

Conditional expression of the mutant Ifitm5 allele results in abnormal cartilage development, leading to growth restriction and progressive joint deformity in Rosa26^{mlfifm5};Prx1-Cre mice.

Rosa26^{mlfifm5};Prx1-Cre mutant mice showed reduced weight gain, and significantly shortened femurs as compared to littermate controls (**Fig. 3A, B and Fig. S2**). Histological sections of the tibial proximal growth plate at P.14 showed disorganization of the columnar structure of the proliferative and hypertrophic zones in the mutant mice. Most notably, the hypertrophic zone was reduced, as demonstrated by immunohistochemistry staining for type X collagen, a marker of hypertrophic chondrocytes (**Fig. 3C, D**).

Studies have shown that *Prx1*-expressing cells in the periosteum serve as a reservoir for osteo-chondroprogenitor cells during bone development and fracture healing (23, 24). Therefore, we next tested whether shortened femurs in the *Rosa26^{mlfifm5};Prx1-Cre* mutant mice are due to the defect of periosteal progenitor cell population or due to the defect of their differentiation. We

performed flow cytometry analysis of periosteal skeletal progenitors by negative selection for hematopoietic (CD45), endothelial (CD31) and erythroid (Ter119) lineage markers, and positive selection for CD105 and CD140a (25). Notably, this analysis demonstrated a significant increase in the percentage of periosteal CD45⁻CD31⁻Ter119⁻CD105⁺CD140a⁺ population in *Rosa26^{mlfifm5}*;Prx1-Cre mutant mice (5.07 %) compared to littermate controls (2.55 %) (**Fig. 4A,B**), whereas skeletal progenitor cell population in the bone marrow was not different (**Fig. 4B** and **Fig. S5**). These data further support the impact of the OI type V mutation on skeletal progenitors as a potential driver of the phenotype.

Skeletal preparations at P.21 showed irregular structure of the proximal long bones, with cartilaginous material accumulating in periarticular tissues (**Fig. 5A** and **Fig. S6**). At age 2 months, skeletal radiographs revealed partial joint ossification, leading to joint deformities and contractures at the knees and ankles (**Fig. 5B**). Histology revealed progression of the abnormal growth plate ultrastructure, with cartilage overgrowth and disruption of the endochondral ossification at the proximal tibial metaphysis (**Fig. 5C**). In contrast, growth was not significantly altered in the *Rosa26^{mlfifm5/+}*;OC-Cre/- or in *Rosa26^{mlfifm5/+}*;Colla1-Cre/- mice that express the mutant allele in more mature osteoblasts (**Fig. S3** and **Fig. S4**).

Increased ERK signaling contributes to abnormal skeletal phenotype in OI type V models.

To study the molecular consequences of the IFITM5 mutation in bone, we performed a proteomic analysis in calvaria of our previously reported transgenic mouse model that constitutionally overexpressed the mutant *Ifitm5* from the *Colla1* 2.3kb promoter (19). Reverse Phase Protein Array (RPPA) analysis detected elevated ERK1/2 phosphorylation (**Fig. 6A, B**). This correlated with immunohistochemistry staining for phosphorylated ERK in

1 *Rosa26^{mIfitm5};Prx1-Cre* mice, that showed abundant positive staining in chondrocytes adjacent to
 2 the ossification centers at the proximal tibia (**Fig. S7**). To understand the functional
 3 consequences of increased ERK activation, we then generated an *in vitro* cell culture model of
 4 OI type V that stably overexpresses the mutant *Ifitm5* in MC3T3 cells under doxycycline
 5 induction. Consistent with the observations in OI type V mouse models, expression of mutant
 6 IFITM5 in MC3T3 cells was associated with increased ERK phosphorylation and delayed
 7 mineralization *in vitro* (**Fig. S7**). The delayed mineralization observed in this cell model was
 8 consistent with the effect on cultured calvarial osteoblasts in the previously published OI type V
 9 mouse models (19, 20). Importantly, treatment with the ERK inhibitor U0126 restored
 10 mineralization in MC3T3 *mIfitm5* mutant cells in a dose-dependent manner (**Fig. S7**).

11 To test the relationship between ERK activation and abnormal cartilage formation in OI
 12 type V, we generated a zebrafish (*Danio rerio*) model of OI type V and performed *in vivo* rescue
 13 experiments. Mutant *IFITM5* mRNA was injected to zebrafish embryos at the one cell stage [30
 14 minutes to 1 hour post fertilization (*hpf*)]. Subsequently, 34% of the embryos at 5 days post
 15 fertilization (*dpf*) showed abnormal morphology (abnormal craniofacial cartilage development
 16 and curved/kinked tail), compared to only 5-10% in control groups that were injected with either
 17 wild type IFITM5, or mCherry mRNA (**Fig. 6C,D**). Treatment with the pharmacologic
 18 MEK/ERK inhibitor PD0325901 significantly increased the proportion of IFITM5 mutant
 19 zebrafish that survived with typical development by 18% at 5 *dpf* (**Fig. 6D**).

20
 21 *Altered spatio-temporal expression of SOX9 impairs chondrogenic maturation and disrupts*
 22 *endochondral bone formation in OI type V models.*

1 The RPPA analysis also detected increased level of SOX9, a master regulator of cartilage
 2 development, in protein extracted from the mutant transgenic mice calvaria (**Fig. 7A, B**).
 3 Therefore, we studied the expression of SOX9 in the conditional *Rosa26^{mlfifm5}*;Prx1-Cre mutant
 4 mice that showed disruption of the growth plate structure and cartilage overgrowth (**Fig. 3, 5**).
 5 Immunohistochemistry for SOX9 in proximal tibia sections at P.14 identified increased staining
 6 intensity and altered spatial distribution of SOX9-positive cells in the growth plate, with
 7 persistence of SOX9 staining in hypertrophic chondrocytes (**Fig. 7C**). Notably, western blot
 8 analysis in ATDC5 chondrogenic cells demonstrated that wild type IFITM5 was co-induced with
 9 SOX9 expression during chondrogenic differentiation (**Fig. S8**).

10 Prx1-Cre transgenic mice express the *Cre* recombinase in mesenchymal cells that
 11 differentiate to osteogenic and chondrogenic lineages. As mature osteoblastic lineage expression
 12 of mutant IFITM5 did not lead to abnormal skeletal phenotype, we explored whether cartilage-
 13 specific expression was sufficient to cause the skeletal phenotype. Thus, we studied the effect of
 14 postnatal activation of the mutant *Ifitm5* allele in chondrocytes via inducible *Rosa26^{mlfifm5}*;Acan-
 15 *Cre ERT2* mice. Similar to the findings in the Prx1-Cre mouse model, expression of mutant
 16 *Ifitm5* in chondrocytes under Aggrecan promoter at P.10 disrupted the growth plate architecture,
 17 leading to disorganized columnar structure and reduced hypertrophic zone, as shown by H&E
 18 staining and SOX9 immunohistochemistry (**Fig. 8A,B**). Immunohistochemistry staining showed
 19 altered spatio-temporal expression of SOX9 and type X collagen in the mutant samples (**Fig.**
 20 **8B,C**). Not surprisingly, *Rosa26^{mlfifm5}*;Acan-*Cre ERT2* mutant mice exhibited a milder, but
 21 significant growth defect and low bone mass, phenocopying the *Rosa26^{mlfifm5}*; Prx1-Cre mice
 22 (**Fig.8D,E**). Moreover, biomechanical testing via 3-point bending showed reduced ductility and
 23 increased bone stiffness in the *Rosa26^{mlfifm5}*;Acan-*Cre ERT2* mutant mice (**Fig. S9**). To evaluate

whether increased SOX9 is a driver of the skeletal phenotype, we intercrossed the *Rosa26^{mlfifm5};Acan-Cre ERT2* mice to *Sox9^{fllox}* mice. Postnatal genetic deletion of *Sox9* in cells expressing the mutant IFITM5 significantly improved the growth plate architecture, as shown by H&E staining, and by immunohistochemistry for SOX9 and type X collagen (**Fig. 8A-C**). Furthermore, micro CT analysis demonstrated partial rescue of the growth restriction and low bone mass phenotype in *Rosa26^{mlfifm5};Sox9^{fl/+};Acan-Cre ERT2* mice (**Fig. 8E**).

OI type V is an osteochondrodysplasia.

The OI type V mouse models reported here recapitulate, at least in part, the human phenotype by exhibiting low bone mass, expansile cartilage formation, and growth restriction (9, 10). They exhibit similar histologic and radiographic features to those reported in the human patients (8), including immature bone matrix with mesh-like appearance (**Fig. 2B**) and sclerotic bands in the femur metaphysis (**Fig. 5B**). Additionally, *Rosa26^{mlfifm5};Prx1-Cre* mice demonstrate joint deformities. To correlate this finding with the human phenotype, we performed a retrospective chart review of seven individuals with OI type V from 3 skeletal centers in the United States and identified variable degree of joint dysfunction in six of the seven participants (85%, **Fig. S11 and Table S1**). Taken together, our data suggest that mutant IFITM5 expression leads to abnormal chondrogenesis while inhibiting osteo-chondroprogenitor cells' maturation into bone. To support this hypothesis, we crossed the *Rosa26^{mlfifm5};Acan-Cre ERT2* mice with Ai9 reporter mice (B6.Cg-*Gt(ROSA)26Sor^{tm9(CAG-tdTomato)Hze}/J*), and traced reporter-positive cells 3 weeks following post-natal activation of the mutant *Ifitm5* allele. In *Rosa26^{mlfifm5}/Ai9;Acan-Cre ERT2* mice, cells co-expressing the Ai9 reporter and mutant *Ifitm5* showed altered distribution with retention in the growth plate area and decreased migration to the femur shaft (**Fig. 9 A-B**),

1 consistent with decreased differentiation into osteoblasts, whereas in littermates controls *Acan-*
2 *Cre ERT2*⁺ cells marked with Ai9 reporter showed the expected pattern of migration along the
3 diaphysis (26). Next, we performed total RNA sequencing in *Rosa26^{mIfitm5};Acan-Cre ERT2*
4 mouse femurs to search for downstream transcriptomic changes in the long bones following
5 activation of the mutant *Ifitm5* allele in chondrocytes. GO enrichment analysis in mutant femurs
6 revealed enrichment for chondrocyte morphogenesis, proliferation, and differentiation processes
7 (**Fig. 9C**). A focused differential gene expression analysis demonstrated up-regulation of
8 chondrogenic markers and down-regulation of osteoblast markers (**Fig. 9D**). Consistent with this
9 observation, activation of the mutant *Ifitm5* allele in cultured marrow stromal cells via soluble
10 Cre recombinase was associated with decreased osteoblastic differentiation and enhanced cell
11 condensation towards chondrogenic differentiation *in vitro* (**Fig. S12**).

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

1 DISCUSSION

2 OI type V is one of the more common causes of moderate to severe OI, second only to
 3 collagen I related forms (5-7). The pathogenic mechanism in OI type V is unknown, hindering
 4 the development of efficient and targeted therapies. We have previously generated a transgenic
 5 mouse model by overexpressing *Ifitm5* cDNA with the novel start codon, corresponding to the
 6 recurrent human OI type V mutation, under the control of the *Colla1* 2.3 kb promoter (19). The
 7 mutant *Ifitm5* transgenic mice exhibited perinatal lethality and severe bone deformities while
 8 transgenic mice overexpressing wild type *Ifitm5* did not show significant abnormalities (19).
 9 Consistent with our transgenic mouse model, others subsequently published a CRISPR/Cas9
 10 knock-in mouse model that also exhibited a severe OI phenotype with perinatal lethality (20, 21),
 11 suggesting that a conditional, tissue and stage-specific expression of the mutant *Ifitm5* may be an
 12 effective approach for mechanistic analyses. We report here the first conditional mouse model
 13 for OI type V that expresses mutant IFITM5 in three different cell types, i.e., limb mesenchymal
 14 cells, osteogenic cells, and chondrogenic cell lineages. Mice expressing the mutant *Ifitm5* allele
 15 are viable and recapitulate the low bone mass and exuberant cartilage formation that is observed
 16 in humans with OI type V.

17 The phenotypic similarity and overlapping severity between the *Rosa26^{mIfitm5};Prx1-Cre*
 18 and *Rosa26^{mIfitm5};Acan-Cre ERT2* mice support that abnormal chondrogenesis is a major
 19 contributor to the skeletal phenotype. The expression of *IFITM5* in cartilage has been
 20 demonstrated in humans and mice (9, 15). Transcriptomic analysis has shown enrichment of
 21 *IFITM5* mRNA during chondrogenesis in human bone marrow mesenchymal cells (17), and in
 22 developing chick embryos (27). We confirmed this finding by showing that expression of the
 23 IFITM5 is upregulated in conjunction with SOX9 in differentiating chondrogenic ATDC5 cells

(**Fig. S8**). In *Rosa26^{mlfitm5};Prx1-Cre* mice, expression of the mutant *Ifitm5* in mesenchymal progenitors of the osteo-chondrogenic lineage was associated with low bone mass and growth restriction, while the *Rosa26^{mlfitm5};Colla1-Cre* and *Rosa26^{mlfitm5};OC-Cre* mice that expressed the mutant *Ifitm5* in committed or mature osteoblasts did not exhibit significant skeletal abnormalities (**Fig. 2, 3 and Fig. S3, S4**).

Previously published OI type V mouse models demonstrated a severe reduction in osteoblast differentiation, and replacement of the normal bone tissue with cartilaginous matrix (19, 20). It is possible that the expression of the mutant IFITM5 in skeletal progenitor cells alters their lineage differentiation in early development. Consistent with this hypothesis, we found that the percentage of periosteal skeletal progenitor cells was significantly increased in the mutant *Rosa26^{mlfitm5};Prx1-Cre* mice (**Fig. 4A, B**). Moreover, histological sections in 2 months old *Rosa26^{mlfitm5};Prx1-Cre* mice showed the failure of chondrogenic terminal differentiation and impaired endochondral ossification (**Fig. 5C**). In the *Rosa26^{mlfitm5};Acan-Cre ERT2* mutant mice that have an overlapping skeletal phenotype with the *Rosa26^{mlfitm5};Prx1-Cre* model, tracing of cells co-expressing the Ai9 reporter and mutant *Ifitm5* showed decreased differentiation to osteoblasts, and bone transcriptome showed enrichment for chondrogenic markers expression (**Fig. 9**). These data suggest that the mutant IFITM5 can maintain or induce osteo-chondro progenitor numbers while inhibiting their terminal differentiation. This then can reduce the pool of osteoblastic cells derived from progenitors in the growth plate (28).

The biochemical mechanisms whereby the mutated IFITM5 protein causes the skeletal pathology in OI type V are not well-understood. Unlike other forms of OI that are associated with abnormalities in type I collagen (i.e., qualitative or quantitative defects of type I collagen, and abnormal processing of type I collagen), our previous transgenic mouse model failed to

1 reveal any significant change in the distribution of collagen throughout the bone or in its post-
 2 translational modifications (19). Since IFITM5 forms part of a protein complex at the membrane
 3 (29) and the localization of the mutant IFITM5 is not altered (30), it is possible that a
 4 neomorphic effect on protein-protein interactions at the plasma membrane may alter downstream
 5 signaling cascades. Proteomic analysis using RPPA identified increased levels of phosphorylated
 6 ERK1/2 in the calvaria of transgenic *Ifitm5^{c.-14C>T}* mice. Further studies in cells and zebrafish
 7 overexpressing mutant IFITM5 support that activation of this pathway is involved in the
 8 mineralization defect and abnormal cartilage development in OI type V (**Fig. 6 and Fig. S7**). The
 9 ERK/MAPK signaling pathway has a critical role in both cartilage and bone development.
 10 Previous studies have shown that this pathway may regulate osteoblast differentiation by
 11 activating downstream RUNX2 and OSX-mediated transcription of osteogenic genes (31). ERK
 12 signaling has been implicated in pigment epithelium derived factor (PEDF)-mediated regulation
 13 of osteoblast maturation and mineralization (32). Inactivation of ERK1 and ERK2 in
 14 mesenchymal osteo-chondroprogenitor cells in the *ERK1^{-/-}; ERK2^{flox/flox}*; Prx1-Cre mice
 15 disrupted osteoblast differentiation and resulted in severe bone deformities (33). In agreement
 16 with these findings, activation of MAPK signaling via transgenic overexpression of a
 17 constitutively active MEK1 stimulated osteoblast differentiation and mineralization (34).
 18 Conversely, somatic mosaicism for gain-of-function mutations in *MAPK2* in melorheostosis was
 19 associated with increased osteoid formation and decreased mineralization *in vivo*, and impaired
 20 osteoblast differentiation *in vitro* (35). Activation of ERK signaling was also implicated in the
 21 mechanism of a rare form of OI due to loss-of-function variants in *CCDC134* (36). These
 22 seemingly conflicting effects suggest a cell and stage-specific action of this pathway, and likely a
 23 crosstalk with other signaling events during osteoblast differentiation (37, 38).

Co-activation of ERK signaling and SOX9 expression has been reported in differentiating osteoblasts (39) and in developing cartilage (40), and they are both important regulators of skeletal development throughout osteochondral differentiation. SOX9 is regulated by the ERK/MAPK signaling pathway (39, 41, 42). We observed altered spatio-temporal expression of *Sox9* and increased SOX9 protein level in our mouse models. Moreover, genetic deletion of *Sox9* in cells expressing mutant IFITM5 led to improvement in the growth plate architecture and improved the low bone mass phenotype (**Fig. 8**), supporting that SOX9 plays a critical role in the pathological mechanism of OI type V. SOX9 is a master transcription factor in chondrocyte differentiation (43, 44), and is downregulated in hypertrophic chondrocytes. Persistent expression of *Sox9* in the hypertrophic zone disrupts terminal chondrocyte maturation and endochondral bone formation (45-47). Interestingly, impaired chondrocyte hypertrophy, as seen in *Rosa26^{mlfitm5}*; Prx1-Cre mutant mice (**Fig. 3C, D**), has been reported in mouse models that have constitutively activated FGFR3 and MAPK signaling (48-52). In mice expressing the thanatophoric dysplasia type II activating *FGFR3* mutation, the defect in chondrocyte maturation and bone formation was linked to increased SOX9 protein stability (51, 52). Moreover, *Sox9* has been shown to down regulate *Runx2* (53), or inhibit its activity (54), during both chondrocyte hypertrophy and endochondral ossification. In humans, campomelic dysplasia caused by *SOX9* haploinsufficiency is associated with chondrocyte hypertrophy and increased RUNX2 level (44, 54). Hence, gain of SOX9 function can affect not only chondrogenesis, but also bone formation derived from chondrogenic cells in the growth plate.

Conditional expression of the mutant *Ifitm5* in the *Rosa26^{mlfitm5}*;Prx1-Cre and *Rosa26^{mlfitm5}*;Acan-Cre ERT2 mice resulted in low bone mass phenotype, as seen in individuals with OI type V. Biomechanical testing in the *Rosa26^{mlfitm5}*;Acan-Cre ERT2 model demonstrated

1 reduced ductility and increased bone stiffness, correlating with the findings in other OI mouse
2 models (55, 56). Although not associated with rhizomelic short stature, OI type V can present
3 with variable longitudinal growth restriction (9, 10), and clinical observations have led others to
4 suggest a defect in growth plate development and function (10, 57). Our mutant mice exhibit
5 cartilage overgrowth at the knees and ankles that progresses to joint contractures (**Fig. 5**).

6 Interestingly, severe joint contractures and ankylosis have been reported in some individuals
7 with OI type V (58). In a small cohort of patients, we discovered milder joint dysfunction, most
8 frequently manifested as limited range of motion at the hips and elbows (**Fig. S11, Table S1**).

9 A limitation of our model is the expression of the mutant protein from the *Rosa* locus.
10 The *Prx1*-Cre mouse model targets cells of the limb bud and cranial mesenchyme, while sparing
11 the axial skeleton, and thus was not suitable to model scoliosis or other spinal abnormalities.
12 Our mouse models demonstrated abnormal cartilage formation, but they did not recapitulate the
13 hypertrophic callus or calcification of interosseous membranes as seen in the human patients.
14 However, the similar tissue abnormalities with human studies both here and in the literature, the
15 findings in heterologous systems in zebrafish and cell models (MC3T3), and the rescue of both
16 cell and fish phenotypes with ERK inhibition and of the mouse phenotype by genetic deficiency
17 of *Sox9*, together support the relevance of these mechanistic findings to the human condition.

18 In summary, we present here a conditional mouse model for OI type V, expressing the
19 mutant *Ifitm5* allele under *Rosa26* promoter. Conditional expression of mutant *Ifitm5* in cells of
20 the osteo-chondroprogenitor, or chondrogenic lineages, resulted in low bone mass, growth
21 restriction, cartilage overgrowth and joint deformities, mimicking the human phenotype.
22 Importantly, we demonstrated a chondrogenesis defect that, together with a mineralization
23 defect, is likely driven by activated ERK signaling and elevated SOX9 downstream of the

IFITM5 mutation. The rescue by ERK inhibition and *Sox9* deficiency points to potential therapeutic approaches for this disorder and have a broader impact on the understanding of mechanisms governing skeletal homeostasis.

1 METHODS

2 Sex as a biological variable: Both male and female mice were used for described experiments.

3 For zebrafish study, sex-specific differences were not considered because zebrafish sex
4 differentiation occurs at 21-23 days post fertilization, while all experiments reported here were
5 concluded by day 5 post fertilization. The human study included both male and female
6 participants.

7 Ifitm5 conditional Rosa26 knock-in mouse model: We generated a knock-in *Rosa26* mouse
8 model by introducing the mutant *Ifitm5* cDNA (m*Ifitm5*) into the *Rosa26* locus using previously
9 described approaches(22, 59). The murine *Ifitm5* cDNA was introduced into pCMV-Tag1 vector
10 to add an in-frame Flag tag at the c terminus, and *in vitro* mutagenesis was performed to obtain
11 the c.-14C>T mutation. The Flag-tagged mutant cDNA was then introduced to pRosa26-DEST
12 vector using Gateway recombination cloning. pRosa26-DEST was a gift from Nick Hastie &
13 Peter Hohenstein [Addgene plasmid # 21189; <http://n2t.net/addgene:21189>;
14 RRID:Addgene_21189 (59)]. Targeting of the construct to the *Rosa26* locus in C57BL/6N
15 mouse embryonic stem (ES) cells (JM8A3) was performed via electroporation by the Genetically
16 Engineered Rodent Model core at Baylor College of Medicine (BCM). ES cell clones were
17 screened for correct targeting by PCR amplification of the 5' region, the knocked-in *Ifitm5*
18 cDNA insert, and the 3' region within *Rosa26* locus (**Table S2**). Correct copy number
19 (heterozygosity) of the knocked-in allele was validated by real time PCR using Neo TaqMan
20 gene dosage assay. Following initial PCR screening, selected clones were validated by southern
21 blotting, as previously described(22). Correctly targeted ES cells were then expanded and
22 assessed for morphology and karyotyping prior to generation of chimeric animals via
23 microinjection and transfer of C57BL/6NTac-A^{tm1.1Arte}, Tyr^{tm1Arte} (Taconic model number 11227)

blastocysts. Sanger sequencing confirmed the insertion of knocked-in allele in founder animals. Chimeras were crossed to C57BL/6NTac-A^{tm1.1Arte}, Tyr^{tm1Arte} mice to generate N1 animals, inheritance of the knock-in allele in N1 animals was confirmed by Sanger sequencing, and the N1 generation was backcrossed to C57BL/6 to generate N2 mice. For all studies described, mice were maintained on a C57BL/6 genetic background. Mice that are heterozygous for the *Rosa26* knock-in mutant *Ifitm5* allele (*Rosa26^{mIfitm5/+}*) were crossed to Cre-recombinase expressing mouse lines (*Cre*^{-/-}), to generate the following genotypes: mutant (*Rosa26^{mIfitm5/+}; Cre*^{-/-} mice) and littermate controls (including *Cre*^{-/-} mice, *Rosa26^{mIfitm5/+}* mice, and *Rosa26^{+/+}* mice). The Cre mouse lines that were used include the Paired related homeobox 1-Cre (Prx1-Cre) transgenic line, the Osteocalcin-Cre (OC-Cre) transgenic line, the rat 2.3 kb *Colla1* transgenic line Tg(*Colla1*-cre)2Bek (*Colla1*-Cre), and the *Agc1^{tm(IRES-CreERT2)}* line (*Acan-Cre ERT2*) that expresses tamoxifen-inducible CreER^{T2} from the aggrecan promoter. The *Acan-Cre ERT2* inducible Cre recombinase was activated by administration of Tamoxifen (10 mg/kg/dose) via intraperitoneal injections, starting at P.10 and until P.15. For *Sox9^{fl}* rescue experiments, *Rosa26^{mIfitm5};Acan-Cre ERT2* mice were crossed to *Sox9^{fl/fl}* mice, Cre recombinase was activated as above, and the following littermates were collected for analysis: *Rosa26^{mIfitm5};Sox9^{fl/+};Acan-Cre ERT2* and *Sox9^{fl/+};Acan-Cre ERT2* (in comparison to *Rosa26^{mIfitm5};Acan-Cre ERT2*). In addition, *Rosa26^{mIfitm5};Acan-Cre ERT2* mice were crossed to *Rosa26* knock-in tdTomato reporter line (B6.Cg-*Gt(ROSA)26Sor^{tm9(CAG-tdTomato)Hze}/J*, here referred to as Ai9 reporter mice) to generate *Rosa26^{mIfitm5/Ai9};Acan-Cre ERT2* mice.

Generation of IFITM5-expressing zebrafish: The expression of mutant IFITM5 in zebrafish (*Danio rerio*) was achieved by injecting zebrafish embryos (*AB* strain) with mutant human *IFITM5* mRNA at the one cell stage [30 minutes to 1 hour post fertilization (*hpf*)]. In brief, the

human wild type or mutant *IFITM5* cDNA was introduced into pCS2+ expression vector. To obtain the human *IFITM5* cDNA, total mRNA was extracted from induced pluripotent stem cells (iPSCs) that were generated from an individual with OI type V and differentiated into osteoblasts for 14 days, using previously described methods (60, 61). Total mRNA served as a template to generate cDNA (Superscript III First Strand RT-PCR kit, Invitrogen) and mutated or wild type *IFITM5* cDNAs were amplified (**Table S2**). Mutated and wild type *IFITM5* mRNA, or mCherry mRNA, were transcribed *in vitro* from pCS2+ vector using mMessage SP6 transcription kit (Invitrogen), and 100 pg were injected/embryo. At 120 *hpf*, embryos were fixed in 4% paraformaldehyde and then stained in 0.1% Alcian blue solution. For ERK/MEK inhibitor rescue experiments, embryos were injected with mutant *IFITM5* mRNA, then randomly allocated at 5 *hpf* to treatment (InSolution MEK1/II Inhibitor III, PD0325901, EMD Millipore at 0.5 μ M) or control (DMSO) groups. Treatment was applied daily to fresh E3 water and at 120 *hpf* embryos were fixed and stained as above for morphology assessment.

Cell culture: All cells were cultured at 37°C and 5% CO₂ in a humid environment. MC3T3-E1 or ATDC5 cells (ATCC) were cultured according to ATCC guidelines. A Tet-on system was employed to stably express *Ifitm5^{c.-14C>T}* under Doxycyclin induction in MC3T3 cells. In brief, cells were transfected with a *piggyBac*-based system to insert two transgenes into the genome: *Ifitm5^{c.-14C>T}* (pTight-TRE- *Ifitm5^{c.-14C>T}*) and rtTA (Tetracycline responsive transactivator, pCMV-rtTA). Transfected cells were selected with 2 μ g/mL puromycin (Gibco) and 500 μ g/mL G418 (Gibco). Stable cells were maintained in growth media (alpha MEM with 10% fetal bovine serum, 1% glutamine and 1% penicillin/streptomycin) containing Puromycin and G418. *Ifitm5^{c.-14C>T}* expression was induced by Doxycycline administration (1.2 μ M; Sigma-Aldrich). For *in vitro* osteogenic differentiation, cells were incubated for 14 days in growth media (alpha MEM

with 10% fetal bovine serum, 1% glutamine and 1% penicillin/streptomycin), containing beta glycerophosphate (10 mM, Sigma-Aldrich), ascorbic acid (100 ug/ml, Sigma-Aldrich) and BMP2 (100 ng/ml, R&D Systems). ERK inhibitor rescue was studied by applying U0126 (Millipore Sigma, at 5 or 10 uM) or vehicle (methanol). Alizarin red S staining was performed after fixation of cells with 4% formalin. For *in vitro* chondrogenic differentiation of ATDC5, cells were incubated for 21 days in growth media (DMEM/F12 with 10% fetal bovine serum, 1% glutamine and 1% penicillin/streptomycin), containing ITS supplement (Insulin-Transferrin-Selenium, Gibco).

Marrow stromal cells (MSC) differentiation *in vitro*: Flushed bone marrow cells from *Rosa26* knock-in mutant *Ifitm5* mice (*Rosa26^{mIfitm5/+}*) were treated with 2uM TAT Cre-recombinase (Excellgen, EG-1001) in low-serum growth media (alpha MEM with 1% fetal bovine serum, 1% glutamine and 1% penicillin/streptomycin) to activate the *Ifitm5* mutation. For osteoblast differentiation, MSC were plated at 8×10^5 /ml into 12-well plate, incubated with Cre-recombinase overnight, and allowed to recover for 24 hours in serum-rich growth media (20% fetal bovine serum). Osteogenic differentiation media (alpha MEM with 10% fetal bovine serum, 1% glutamine, 1% penicillin/streptomycin, 10 mM beta glycerophosphate and 100 ug/ml ascorbic acid) was applied to confluent cultures and changed every other day for a total of 7 days before RNA was extracted for qPCR analysis. For chondrogenic differentiation, MSC were pre-treated with Cre-recombinase, then plated at 1.5×10^6 /ml (150,000 cells/well) into v-shaped 96-well plates and span-down (500g, 5 min) to pellet culture. Chondrogenic media (StemXVivo[®] Chondrogenic Media and Chondrogenic Supplement, R&D Systems) was refreshed every 3 days for a total of 21 days. Cells were fixed in 4% glutaraldehyde and stained

with Alcian Blue. Condensed cartilaginous structures were embedded in OCT media (Tissue-Tek® O.C.T. Compound, Sakura), and cryo-sectioned at 7 μ m for staining.

Isolation and flow cytometry analysis of periosteal and bone marrow skeletal progenitor cells: To

isolate periosteal cells, dissected femurs and tibia were placed in PBS and the overlying muscle were carefully removed. Bones were then incubated in ice-cold 1% FBS for 15 minutes, and the loosely associated periosteum was scraped off using forceps. The periosteal tissues were

incubated with 0.2% collagenase and 10% FBS in PBS at 37°C for one hour. The dissociated periosteal cells were washed in PBS, filtered with a 40- μ m cell strainer, and resuspended at

$\sim 1 \times 10^7$ cells/mL. To isolate bone marrow cells, femurs and tibia cleaned of periosteum were

crushed in 1% FBS using a mortar and pestle. The remaining bone was further fragmented using dissection scissors. The bone fragments in 1% FBS were washed then incubated in 0.2%

collagenase and 10% FBS in PBS at 37°C for one hour, as previously described(62). After

incubation the dissociated cells were washed in PBS, filtered through a 40- μ m cell strainer, and

resuspended at $\sim 1 \times 10^7$ cells/mL. To analyze skeletal stem/progenitor cell population, cells were

stained with CD45-pacific blue (clone:30-F11), CD31-eFluor 450 (clone:390), and Ter119-

BV605 (clone: Ter119) in combination with CD140a-APC (clone: APA5) and CD105-PE-Cy7

(clone: MJ7/18). Antibodies were purchased from eBioscience. DAPI was used for viable cell

gating. Flow cytometric experiments were performed in the BCM Cytometry and Cell Sorting

Core using an LSR Fortessa (BD biosciences, San Jose, CA). Data were analyzed with FlowJo

Software (TreeStar, Ashland, OR) and represented as dot plots of fluorescence intensity.

RNA extraction, real-time qPCR and RNA sequencing: Bone tissues (femur or tibia) were

collected from 2 months old *Rosa26^{mlf1m5/+};Prx1-Cre*, *Rosa26^{mlf1m5/+};OC-Cre* and

Rosa26^{mlf1m5/+};Colla1-Cre mice. Cartilage tissue (rib cage) was collected from

1 *Rosa26^{mIfitm5/+};Acan-Cre* ERT2 mice at P.6 that were activated by Tamoxifen subcutaneous
 2 injection (10 mg/kg/dose) at P.3-P5. Total RNA was extracted in Trizol reagent (Ambion) using
 3 TissueLyser (Qiagen). The iScript cDNA synthesis kit (Bio-Rad) or SuperScript III (Invitrogen)
 4 were used to synthesize cDNA according to the manufacturer's protocol. Real-time qPCR was
 5 performed on LightCycler instrument (Roche) using FastStart Essential DNA Master reagent
 6 (Roche) with *GAPDH* or *B2m* (beta-2 microglobulin) as internal control. For RNA sequencing,
 7 femurs were collected from 5 weeks old *Rosa26^{mIfitm5/+};Acan-Cre* ERT2 mice that were activated
 8 by Tamoxifen intraperitoneal injection (10 mg/kg/dose) at P.10. Total RNA from pulverized
 9 bone was extracted using Trizol reagent (Ambion) and further purified by phenol-chloroform
 10 precipitation. Total RNA (1 ug) was subjected to rRNA-depletion based library preparation and
 11 sequencing (Azenta Life Sciences). Between 25.5 and 34 million paired-end reads were
 12 generated for each sample. The alignment was performed using STAR aligner with mm39 as the
 13 reference genome. Normalization, differential expression, hierarchical clustering, and GO
 14 analysis were then performed using RNA-Seq analysis pipeline in Partek Genomics Suite
 15 (Partek). Differential gene analysis was performed using DESeq2 and statistical significance was
 16 determined by 2-way ANOVA, which is built into the Partek Genomics Suite RNA-Seq analysis
 17 pipeline. The significantly differential expressed genes (fold change >2 and false discovery rate
 18 < 0.05) were then used for GO Analysis. Chondrogenic and osteogenic genes were selected for
 19 heatmap generation based on previous report (63). Protein extraction, Reverse Phase Protein
 20 Array (RPPA), and western blot: Protein was extracted from calvaria of transgenic *Ifitm5^{c-14C>T}*
 21 mice(19) in modified Tissue Protein Extraction Reagent (ThermoFisher Scientific) containing
 22 protease and phosphatase inhibitors cocktail (Roche), using TissueLyser (Qiagen). The protein
 23 concentration was measured using a BCA kit (ThermoFisher Scientific) and the lysate was

1 diluted to 0.5 mg/ml in RPPA lysis buffer containing SDS sample buffer and 0.25% β -
 2 mercaptoethanol. The RPPA was conducted by the Antibody-based Proteomics Core at BCM
 3 using a standardized protocol (64). In total, 8 mutant transgenic (*Ifitm5^{c.-14C>T}*), 8 wild type
 4 transgenic and 8 non-transgenic littermates bone samples were included in the experiment. Each
 5 sample was assayed in 3 technical replicates to account for technical variation. For western blot
 6 analysis, 25-50 ug of total protein was loaded on 4-15% SDS-PAGE gradient gel (Bio-Rad) and
 7 transferred to PVDF membrane (Millipore Sigma). Membrane was blocked in 5% skim milk and
 8 incubated overnight at 4°C with primary antibody: anti-Phospho-p44/42 MAPK (Erk1/2)
 9 Thr202/Tyr204 (Cell Signaling, 9101S), p44/42 MAPK (Erk1/2) (Cell Signaling, 4695S), anti-
 10 SOX9 (EMD Millipore AB5535), anti-IFITM5 (Abcam, ab230863), anti-alpha Tubulin
 11 (Millipore Sigma, T5168) and anti-GAPDH (Millipore Sigma, G9295). Signal was captured by
 12 film or via ChemiDoc imager (Bio Rad).

13 Histology and Immunohistochemistry (IHC): Bone samples from OI type V patient and
 14 unaffected control were obtained when subjects were undergoing skeletal surgery for a medical
 15 indication. The fragments of bone removed during surgery, which otherwise would have been
 16 discarded, were collected, and processed for histology. Mouse hindlimbs were collected at age 2
 17 weeks and 2 months. Tissues were fixed in 4% paraformaldehyde (PFA) overnight at 4°C and
 18 stored in 70% ethanol. Paraffin-embedded tissues were sagittally sectioned at 7 μ m. Hematoxylin
 19 and Eosin staining, Alcian Blue and Nuclear Fast Red staining, were performed according to
 20 standard methods. Toluidine Blue staining was performed using manufacturer's orders
 21 (VitroView). For IHC, samples were deparaffinized, re-fixed in 4% PFA for 30 minutes, and
 22 incubated at 60°C in Target Retrieval Solution, pH 6.1 (Dako) for antigen retrieval. Samples
 23 were treated in 3% hydrogen peroxide for 30 minutes at room temperature, followed by blocking

with 5% normal goat serum. The following primary antibodies were applied overnight at 4°C: anti-COL10A1 (DSHB, Iowa City, IA, USA X-AC9), anti-SOX9 (EMD Millipore AB5535), or anti- Phospho-p44/42 MAPK (Erk1/2) Thr202/Tyr204 (Cell Signaling, 9101S). Anti-rabbit secondary antibody (Vectastain ABC system, Vector Laboratories) was applied, and DAB (Vector SK-4100) staining performed per manufacturer instruction. Slides were stained with Hematoxylin and mounted using Cytoseal XYL xylene-based mounting medium (Thermo Scientific). Images were taken with a light microscope (Axioplan 2, Zeiss), or using Zeiss AxioScan_Z1 whole slide scanner by the BCM RNA In-Situ Hybridization core.

Skeletal radiographs: Radiographic images of *Rosa26^{mlfimt5/+}; Cre*^{-/-} mice were taken with the Kubtec XPERT80 (Kubtec X-ray).

Skeletal preparations: P.21 *Rosa26^{mlfimt5/+}; Cre*^{-/-} mice mutant mice and littermate controls were sacrificed and fixed with 95% Ethanol, then stained overnight in Alcian blue (containing 0.015% Alcian blue 8GX, 20% Acetic acid, and 80% Ethanol 95%), and soaked in 2% KOH solution for 24 hours to remove remnants of soft tissue. Skeletal preps were then stained overnight in Alizarin red solution (containing 0.005% Alizarin red S in 1% KOH), cleared in 1% KOH/20% glycerol solution, and stored in glycerol/95% Ethanol 1:1 solution.

Immunofluorescence imaging: Bones were collected from 5 weeks old *Rosa26^{mlfimt5/Ai9};Acan-Cre* *ERT2* mice, fixed in 4% paraformaldehyde and decalcified in 10% EDTA. Samples were embedded in OCT media (Tissue-Tek® O.C.T. Compound, Sakura), cryo-sectioned at 10 um and mounted to adhesive microscope slides using Tape-Transfer system (Leica). Slides were counterstained with DAPI (IHC World) and sealed using ProLong™ Glass Antifade mounting media (Invitrogen) according to the manufacturer's instructions. Images were acquired with

1 Zeiss LSM 780 confocal microscope in the Optical Imaging and Vital Microscopy Core at BCM.
2 Images were processed with the ImageJ software.

3 Micro-CT analysis: Spines and right femurs were scanned in 70% ethanol using a Scanco μ CT-
4 40 micro-CT system (Scanco Medical, 55kVp and 145 μ A X-ray source), and scans were
5 reconstructed at a 16 μ m isotropic voxel size. Trabecular bone of L4 vertebrae and the distal
6 metaphyses of right femurs were analyzed using Scanco software by manually contouring
7 trabecular bone. For vertebrae, the region of interest (ROI) was defined as the trabecular volume
8 between the L4 vertebral endplates. For femurs, trabecular ROI was defined proximal to the
9 distal femoral growth plate and the number of slides analyzed was adjusted to femoral length
10 (femur length was measured from the top of the femoral head to the bottom of the medial
11 condyle): 75 slides (=1.2 mm) were analyzed for 2 months old Prx1-Cre and OC-Cre mouse
12 models control femurs; 55-60 slides were analyzed for 5 weeks old *Acan-Cre ERT2* control
13 femurs; and 45-50 slides were analyzed for mutant femurs (across all models). Quantification of
14 trabecular parameters was performed using the Scanco software with a threshold value of 230.
15 These parameters include bone volume/total volume (BV/TV), trabecular number (Tb.N) and
16 trabecular thickness (Tb.Th), connectivity density (Conn.D) and tissue mineral density (TMD)
17 (65). Cortical bone parameters of the femoral midshaft were measured at the exact center and at
18 the distal 75% of femur length using the automated thresholding algorithm included in the
19 Scanco software. Trabeculae in contact with cortical bone were manually removed from the ROI
20 (11 slides analyzed per location, threshold 210). The cortical parameters include total cross-
21 sectional area (Tt.Ar), cortical bone area (Ct.Ar), marrow area (Ma.Ar), cortical thickness
22 (Ct.Th), cross-sectional moments of inertia (CSMI), anterior-posterior diameter, and tissue
23 mineral density (TMD) (65). Between six to eight spines and femurs were scanned per group.

Biomechanical measurement: Femurs were collected from 5 weeks old *Rosa26^{mlftm5/+};Acan-Cre* ERT2 mice that were activated by Tamoxifen intraperitoneal injection (10 mg/kg/dose) at P.10. Bones were collected, stripped of soft tissues, wrapped in saline-soaked gauze, and frozen at – 20°C until analyses were performed. The femurs were tested to failure in three-point bending at a rate of 0.1 mm/sec and were oriented in the test fixture such that the anterior surface was in compression and the posterior surface in tension. Femurs were tested wet at room temperature using displacement mode with an Instron 68SC-2 microtester (Instron Inc., Norwood MA). The test fixture span was 3.61mm. A 100N load cell was used to collect data, and load and displacement data were captured at rate of 40Hz by using BLUEHILL Software (Instron 68SC-2). The maximum load was determined by finding the highest load value recorded before the specimen fractured. The region of the load-displacement curve between 1N and the maximum load was separated into 5 segments and the fitted line of the segment with greatest slope was defined as the stiffness. A line representing 10% degradation of this stiffness was used to define the yield point. The elastic region was identified as the region from the completion of the preload to the yield point. The post-yield region was identified as the region from the yield point until point of specimen fracture. Using a trapezoidal numerical integration method, the work to fracture was calculated as the area under the load-displacement curve. The cross-sectional geometry of each bone as determined by microCT image analysis was used to convert the maximum load and stiffness data into ultimate stress and elastic modulus values using beam theory.

OI type V patient chart review: We conducted a retrospective chart review on seven individuals with OI type V at three expert skeletal centers in the U.S.: Baylor College of Medicine, Houston, TX, Oregon Health and Sciences University, Portland, OR, and Omaha Children's Hospital,

Omaha, NE. The following data were collected from the chart review: age, sex, molecular diagnosis of OI type V, presence or absence of typical OI type V clinical features (hyperplastic callus, calcification of the interosseous membrane, radial head dislocation), presence or absence of joint pathology (decreased range of motion, joint contracture, or joint ossification in the shoulders, elbows, wrists, hips, knees and ankles). The data were collected in a standardized format using specific data fields from all three centers.

Statistical methods: All statistical analyses used parametric unpaired tests, including one-way analysis of variance (ANOVA) or Student's *t*-tests. Prism GraphPad software

(<https://www.graphpad.com/scientific-software/prism/>) or SAS 9.4 (SAS Institute Inc., 2007, Cary, NC) was used for the statistical analysis. *P*-values<0.05 were considered significant.

Study approval: Mice and zebrafish were housed in the Baylor College of Medicine Animal Vivarium, and all procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at Baylor College of Medicine. Bone samples from an individual with OI type V and unaffected individual were obtained when these individuals were undergoing skeletal surgery for a medical indication. The fragments of bone removed during surgery, which otherwise would have been discarded, were collected and processed under a protocol approved by the Institutional Review Board (IRB) of Baylor College of Medicine. Informed consent was obtained from the parents or legal guardians prior to collection of samples. For the retrospective chart review, medical records for 6 individuals were reviewed after informed consent was obtained from participants or their legal guardians. These 6 individuals were enrolled in an observational natural history study of osteogenesis imperfecta being conducted by the NIH Rare Diseases Clinical Research Network's Brittle Bone Disorders Consortium (NCT02432625). For

one participant, who was not enrolled in the observational study, written permission was obtained to review and publish deidentified phenotypic data.

Data availability: All data generated or analyzed during this study are included in the manuscript and supporting files. “Supporting data values” file has been provided for all numerical data. RNA sequencing data were deposited to GEO database (accession number GSE268601).

1 AUTHOR CONTRIBUTIONS

2 Conceptualization: RM, BHL

3 Methodology & investigation: RM, IS, MEW, ASB, VCR, LO, YJ, CDL, DB, ECB, MMJ, YC,

4 RC, IL, MA, CL, DNM, CGA, DP, JDH

5 Data acquisition & statistical analysis: BCD, AC, BMS, MJ, SH

6 Subject recruitment and clinical phenotyping: AAT, AT, MW, EO, SCSN

7 Supervision: BHL

8 Writing – original draft: RM, BHL

9 Writing – review & editing: All authors reviewed and edited the manuscript

10

11

12

13

14

15

16

17

18

19

20

ACKNOWLEDGEMENTS

The authors would like to thank the subjects and their families for participation in the study. We thank Fuli Jia and Myra Costello from the Antibody-based Proteomics Core/Shared Resource for their excellent technical assistant in performing RPPA experiments. We thank Drs. Kimal Rajapakshe and Cristian Coarfa for RPPA data processing and normalization. RM was supported by the Michael Geisman Fellowship of the Osteogenesis imperfecta foundation, the Lawrence Family Bone Disease Program of Texas, the BCM Chao Physician-Scientist award and through the NIH/NIGMS T32GM07526. This work was also supported by NIH/NIAMS U54 AR068069 (BHL, MW, MJ, EO), NIH/NIDCR DE031162 (BHL), NIH/NICHHD U54 HD083092 (SCSN) and NIH UL1 TR002369 (EO). BMS was supported by the Rare Diseases Clinical Research Consortium for the Rare Diseases Clinical Research Network's Urea Cycle Disorders Consortium Career Enhancement Core Trainee Award, the NIH T32 DK007664-28 and the US Public Health Service grant P30DK56338, which funds the Texas Medical Center for Digestive Disease Center. ECB was supported by the NIH T32 HL092332. The Antibody-based Proteomics Core was supported in part by the Cancer Prevention & Research Institute of Texas Proteomics & Metabolomics Core Facility Support Award (RP210227, PI Dean P. Edwards), the National Cancer Institute Cancer Center Support Grant (P30CA125123, SH), and the NIH S10 award (S10OD028648, SH). We thank the Genetically Engineered Rodent Models Core at BCM for assistance with mouse production. Resources accessed through the core were supported by a National Institutes of Health grant (P30CA125123 to the Dan L. Duncan Comprehensive Cancer Center). This project was supported by the RNA In Situ Hybridization Core at BCM, which is, in part, supported by a Shared Instrumentation grant from the NIH (S10OD016167). This project was supported by the Cytometry and Cell Sorting Core at BCM with funding from the CPRIT

Core Facility Support Award (CPRIT-RP180672), the NIH (CA125123 and RR024574) and the assistance of Joel M. Sederstrom. This project was supported by the Optical Imaging & Vital Microscopy Core at the Baylor College of Medicine. This work was supported by the Brittle Bone Disease Consortium (BBDC, U54AR068069). The BBDC is a part of the National Center for Advancing Translational Science's (NCATS's) Rare Diseases Clinical Research Network. The BBDC is funded through a collaboration between the Office of Rare Disease Research of NCATS, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Dental and Craniofacial Research, National Institute of Mental Health, and National Institute of Child Health and Human Development (NICHD). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The BBDC was also supported by the Osteogenesis Imperfecta (OI) Foundation. The work was supported by the Clinical Translational Core of Baylor College of Medicine Intellectual and Developmental Disabilities Research Center (P50HD103555) from the Eunice Kennedy Shriver NICHD. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

1 REFERENCES

- 2 1. Marini JC, et al. Osteogenesis imperfecta. *Nat Rev Dis Primers*. 2017;3:17052.
- 3 2. Marom R, et al. Osteogenesis imperfecta: an update on clinical features and therapies. *Eur J*
- 4 *Endocrinol*. 2020;183(4):R95-r106.
- 5 3. Rossi V, et al. Osteogenesis imperfecta: advancements in genetics and treatment. *Curr Opin*
- 6 *Pediatr*. 2019;31(6):708-15.
- 7 4. Jovanovic M, et al. Osteogenesis Imperfecta: Mechanisms and Signaling Pathways Connecting
- 8 Classical and Rare OI Types. *Endocr Rev*. 2022;43(1):61-90.
- 9 5. Bardai G, et al. DNA sequence analysis in 598 individuals with a clinical diagnosis of
- 10 osteogenesis imperfecta: diagnostic yield and mutation spectrum. *Osteoporos Int*.
- 11 2016;27(12):3607-13.
- 12 6. Liu Y, et al. Gene mutation spectrum and genotype-phenotype correlation in a cohort of Chinese
- 13 osteogenesis imperfecta patients revealed by targeted next generation sequencing. *Osteoporos Int*.
- 14 2017;28(10):2985-95.
- 15 7. Trancozo M, et al. Osteogenesis imperfecta in Brazilian patients. *Genet Mol Biol*.
- 16 2019;42(2):344-50.
- 17 8. Glorieux FH, et al. Type V osteogenesis imperfecta: a new form of brittle bone disease. *J Bone*
- 18 *Miner Res*. 2000;15(9):1650-8.
- 19 9. Cho TJ, et al. A single recurrent mutation in the 5'-UTR of IFITM5 causes osteogenesis
- 20 imperfecta type V. *Am J Hum Genet*. 2012;91(2):343-8.
- 21 10. Rauch F, et al. Osteogenesis imperfecta type V: marked phenotypic variability despite the
- 22 presence of the IFITM5 c.-14C>T mutation in all patients. *J Med Genet*. 2013;50(1):21-4.
- 23 11. Semler O, et al. A mutation in the 5'-UTR of IFITM5 creates an in-frame start codon and causes
- 24 autosomal-dominant osteogenesis imperfecta type V with hyperplastic callus. *Am J Hum Genet*.
- 25 2012;91(2):349-57.

- 1 12. Shapiro JR, et al. Phenotypic variability of osteogenesis imperfecta type V caused by an IFITM5
2 mutation. *J Bone Miner Res.* 2013;28(7):1523-30.
- 3 13. Lazarus S, et al. The IFITM5 mutation c.-14C > T results in an elongated transcript expressed in
4 human bone; and causes varying phenotypic severity of osteogenesis imperfecta type V. *BMC*
5 *Musculoskelet Disord.* 2014;15:107.
- 6 14. Takagi M, et al. A recurrent mutation in the 5'-UTR of IFITM5 causes osteogenesis imperfecta
7 type V. *Am J Med Genet A.* 2013;161A(8):1980-2.
- 8 15. Moffatt P, et al. Bril: a novel bone-specific modulator of mineralization. *J Bone Miner Res.*
9 2008;23(9):1497-508.
- 10 16. Patoine A, et al. The osteogenic cell surface marker BRIL/IFITM5 is dispensable for bone
11 development and homeostasis in mice. *PLoS One.* 2017;12(9):e0184568.
- 12 17. Somoza RA, et al. Transcriptome-Wide Analyses of Human Neonatal Articular Cartilage and
13 Human Mesenchymal Stem Cell-Derived Cartilage Provide a New Molecular Target for
14 Evaluating Engineered Cartilage. *Tissue Eng Part A.* 2018;24(3-4):335-50.
- 15 18. Hanagata N. IFITM5 mutations and osteogenesis imperfecta. *J Bone Miner Metab.*
16 2016;34(2):123-31.
- 17 19. Lietman CD, et al. A transgenic mouse model of OI type V supports a neomorphic mechanism of
18 the IFITM5 mutation. *J Bone Miner Res.* 2015;30(3):489-98.
- 19 20. Rauch F, et al. Crispr-Cas9 engineered osteogenesis imperfecta type V leads to severe skeletal
20 deformities and perinatal lethality in mice. *Bone.* 2018;107:131-42.
- 21 21. Hanagata N, et al. Effect of immunosuppressants on a mouse model of osteogenesis imperfecta
22 type V harboring a heterozygous Ifitm5 c.-14C > T mutation. *Sci Rep.* 2020;10(1):21197.
- 23 22. Carofino BL, and Justice MJ. Tissue-Specific Regulation of Oncogene Expression Using Cre-
24 Inducible ROSA26 Knock-In Transgenic Mice. *Curr Protoc Mouse Biol.* 2015;5(2):187-204.
- 25 23. Brown S, et al. The Prrx1eGFP Mouse Labels the Periosteum During Development and a
26 Subpopulation of Osteogenic Periosteal Cells in the Adult. *JBMR Plus.* 2023;7(2):e10707.

- 1 24. Kawanami A, et al. Mice expressing GFP and CreER in osteochondro progenitor cells in the
2 periosteum. *Biochem Biophys Res Commun.* 2009;386(3):477-82.
- 3 25. Deveza L, et al. Comparative analysis of gene expression identifies distinct molecular signatures
4 of bone marrow- and periosteal-skeletal stem/progenitor cells. *PLoS One.* 2018;13(1):e0190909.
- 5 26. Ono N, et al. A subset of chondrogenic cells provides early mesenchymal progenitors in growing
6 bones. *Nat Cell Biol.* 2014;16(12):1157-67.
- 7 27. Gomez-Picos P, et al. Limb Mesoderm and Head Ectomesenchyme Both Express a Core
8 Transcriptional Program During Chondrocyte Differentiation. *Front Cell Dev Biol.*
9 2022;10:876825.
- 10 28. Mizuhashi K, et al. Resting zone of the growth plate houses a unique class of skeletal stem cells.
11 *Nature.* 2018;563(7730):254-8.
- 12 29. Hanagata N, and Li X. Osteoblast-enriched membrane protein IFITM5 regulates the association
13 of CD9 with an FKBP11-CD81-FPRP complex and stimulates expression of interferon-induced
14 genes. *Biochem Biophys Res Commun.* 2011;409(3):378-84.
- 15 30. Patoine A, et al. Topological mapping of BRIL reveals a type II orientation and effects of
16 osteogenesis imperfecta mutations on its cellular destination. *J Bone Miner Res.*
17 2014;29(9):2004-16.
- 18 31. Artigas N, et al. Mitogen-activated protein kinase (MAPK)-regulated interactions between
19 Osterix and Runx2 are critical for the transcriptional osteogenic program. *J Biol Chem.*
20 2014;289(39):27105-17.
- 21 32. Li F, et al. Pigment epithelium derived factor regulates human Sost/Sclerostin and other osteocyte
22 gene expression via the receptor and induction of Erk/GSK-3beta/beta-catenin signaling. *Biochim*
23 *Biophys Acta Mol Basis Dis.* 2018;1864(10):3449-58.
- 24 33. Matsushita T, et al. Extracellular signal-regulated kinase 1 (ERK1) and ERK2 play essential roles
25 in osteoblast differentiation and in supporting osteoclastogenesis. *Mol Cell Biol.*
26 2009;29(21):5843-57.

34. Ge C, et al. Critical role of the extracellular signal-regulated kinase-MAPK pathway in osteoblast differentiation and skeletal development. *J Cell Biol.* 2007;176(5):709-18.
35. Kang H, et al. Somatic activating mutations in MAP2K1 cause melorheostosis. *Nat Commun.* 2018;9(1):1390.
36. Dubail J, et al. Homozygous Loss-of-Function Mutations in CCDC134 Are Responsible for a Severe Form of Osteogenesis Imperfecta. *J Bone Miner Res.* 2020;35(8):1470-80.
37. Schindeler A, and Little DG. Ras-MAPK signaling in osteogenic differentiation: friend or foe? *J Bone Miner Res.* 2006;21(9):1331-8.
38. Kim JM, et al. Biphasic regulation of osteoblast development via the ERK MAPK-mTOR pathway. *Elife.* 2022;11.
39. Song JH, et al. Signaling responses of osteoblast cells to hydroxyapatite: the activation of ERK and SOX9. *J Bone Miner Metab.* 2008;26(2):138-42.
40. Yoshida T, et al. Incoherent Feedforward Regulation via Sox9 and ERK Underpins Mouse Tracheal Cartilage Development. *Front Cell Dev Biol.* 2020;8:585640.
41. Murakami S, et al. Up-regulation of the chondrogenic Sox9 gene by fibroblast growth factors is mediated by the mitogen-activated protein kinase pathway. *Proc Natl Acad Sci U S A.* 2000;97(3):1113-8.
42. Ma N, et al. The regulatory mechanism of p38/MAPK in the chondrogenic differentiation from bone marrow mesenchymal stem cells. *J Orthop Surg Res.* 2019;14(1):434.
43. Lefebvre V. Roles and regulation of SOX transcription factors in skeletogenesis. *Curr Top Dev Biol.* 2019;133:171-93.
44. Haseeb A, et al. SOX9 keeps growth plates and articular cartilage healthy by inhibiting chondrocyte dedifferentiation/osteoblastic redifferentiation. *Proc Natl Acad Sci U S A.* 2021;118(8).
45. Kim Y, et al. Generation of transgenic mice for conditional overexpression of Sox9. *J Bone Miner Metab.* 2011;29(1):123-9.

- 1 46. Hattori T, et al. SOX9 is a major negative regulator of cartilage vascularization, bone marrow
2 formation and endochondral ossification. *Development*. 2010;137(6):901-11.
- 3 47. Lui JC, et al. Persistent Sox9 expression in hypertrophic chondrocytes suppresses
4 transdifferentiation into osteoblasts. *Bone*. 2019;125:169-77.
- 5 48. Ali TM, et al. The recurrent homozygous translation start site variant in CCDC134 in an
6 individual with severe osteogenesis imperfecta of non-Moroccan ancestry. *Am J Med Genet A*.
7 2022;188(5):1545-9.
- 8 49. Lee YC, et al. Knock-in human FGFR3 achondroplasia mutation as a mouse model for human
9 skeletal dysplasia. *Sci Rep*. 2017;7:43220.
- 10 50. Murakami S, et al. Constitutive activation of MEK1 in chondrocytes causes Stat1-independent
11 achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype. *Genes Dev*.
12 2004;18(3):290-305.
- 13 51. Shung CY, et al. Disruption of a Sox9-beta-catenin circuit by mutant Fgfr3 in thanatophoric
14 dysplasia type II. *Hum Mol Genet*. 2012;21(21):4628-44.
- 15 52. Zhou ZQ, et al. Mutant activated FGFR3 impairs endochondral bone growth by preventing SOX9
16 downregulation in differentiating chondrocytes. *Hum Mol Genet*. 2015;24(6):1764-73.
- 17 53. Dy P, et al. Sox9 directs hypertrophic maturation and blocks osteoblast differentiation of growth
18 plate chondrocytes. *Dev Cell*. 2012;22(3):597-609.
- 19 54. Zhou G, et al. Dominance of SOX9 function over RUNX2 during skeletogenesis. *Proc Natl Acad*
20 *Sci U S A*. 2006;103(50):19004-9.
- 21 55. Claeys L, et al. Exploration of the skeletal phenotype of the Col1a1 (+/Mov13) mouse model for
22 haploinsufficient osteogenesis imperfecta type 1. *Front Endocrinol (Lausanne)*.
23 2023;14:1145125.
- 24 56. Bi X, et al. Correlations Between Bone Mechanical Properties and Bone Composition Parameters
25 in Mouse Models of Dominant and Recessive Osteogenesis Imperfecta and the Response to Anti-
26 TGF-beta Treatment. *J Bone Miner Res*. 2017;32(2):347-59.

57. Arundel P, et al. Evolution of the radiographic appearance of the metaphyses over the first year of life in type V osteogenesis imperfecta: clues to pathogenesis. *J Bone Miner Res.* 2011;26(4):894-8.
58. Whyte MP, et al. Coalescing expansile skeletal disease: Delineation of an extraordinary osteopathy involving the IFITM5 mutation of osteogenesis imperfecta type V. *Bone.* 2021;145:115835.
59. Hohenstein P, et al. High-efficiency Rosa26 knock-in vector construction for Cre-regulated overexpression and RNAi. *Pathogenetics.* 2008;1(1):3.
60. Jin Z, et al. Nitric oxide modulates bone anabolism through regulation of osteoblast glycolysis and differentiation. *J Clin Invest.* 2021;131(5).
61. Kho J, et al. Argininosuccinate Lyase Deficiency Causes an Endothelial-Dependent Form of Hypertension. *Am J Hum Genet.* 2018;103(2):276-87.
62. Worthley DL, et al. Gremlin 1 identifies a skeletal stem cell with bone, cartilage, and reticular stromal potential. *Cell.* 2015;160(1-2):269-84.
63. Liu CF, and Lefebvre V. The transcription factors SOX9 and SOX5/SOX6 cooperate genome-wide through super-enhancers to drive chondrogenesis. *Nucleic Acids Res.* 2015;43(17):8183-203.
64. Bu W, et al. Mammary Precancerous Stem and Non-Stem Cells Evolve into Cancers of Distinct Subtypes. *Cancer Res.* 2019;79(1):61-71.
65. Bouxsein ML, et al. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. *J Bone Miner Res.* 2010;25(7):1468-86.

Figure 1A-B





Fig. 1: Conditional *Rosa26* knock-in *mIfitm5* mouse model. The mutant mouse *Ifitm5* cDNA was cloned into the *Rosa26*-DEST vector downstream of a loxP-polyA-loxP stop cassette. Schematic representation also indicates the approximate location of PCR screening primers (in ES cells, A) and genotyping primers (in mice, B).

Figure 2A




1 **Figure 2B**

Figure 2C





Fig. 2: Conditional expression of the mutant *Ifitm5* allele results in low bone mass in

***Rosa26^{mIfitm5/+};Prx1-Cre* mice.** (A) Micro CT analysis in femurs showed significant decrease in bone architectural parameters in *Rosa26^{mIfitm5/+};Prx1-Cre/-* mutants, including the bone volume/total volume (BV/TV), and trabecular number. Consistently, trabecular spacing was increased. Cortical thickness was not significantly altered. Analysis performed in 2 months old males (One-way ANOVA with Tukey's post-hoc tests, n=7 per group, all comparisons to mutant group. **p<0.001). (B) Histological sections show immature mesh-like bone matrix in *Rosa26^{mIfitm5/+};Prx1-Cre/-* mice, as seen in individuals with OI type V. Toluidine blue and Hematoxylin & Eosin staining in *Rosa26^{mIfitm5/+};Prx1-Cre/-* mice and littermate control (upper and middle panel). Bottom panel showing human OI type V bone section for comparison. Scale bar=200 um. (C) Micro CT analysis of femur and spine BV/TV showing no significant difference in *Rosa26^{mIfitm5/+};Oc-Cre/-* mice. Analysis performed in 2 months old males (One-way ANOVA with Tukey's post-hoc tests resulted not significant, n=5-7 per group, all comparisons to mutant group).

Figure 3A-B



B

Rosa26^{mfitm5}/+ ;

Control Prx1-Cre/-




1 **Figure 3C**

Figure 3D





Fig. 3: Conditional expression of the mutant *Ifitm5* allele results in growth restriction and abnormal growth plate architecture in *Rosa26^{mIfitm5/+};Prx1-Cre* mice. (A) The body weight and femur length are reduced by 10-15% and 40-50%, respectively in *Rosa26^{mIfitm5/+};Prx1-Cre/-* mutants (a summary of measurements in 2 months old male, one-way ANOVA with Tukey's post-hoc tests, n=7 per group, all comparisons to mutant group. *p< 0.05, **p<0.005, ***p<0.0001). (B) A representative micro CT image of control (left) and mutant (right) femur. (C) Representative histology images of proximal tibia of control (left panel) and mutant (*Rosa26^{mIfitm5/+};Prx1-Cre/-*, right panel) mice at age 2 weeks, Hematoxylin & Eosin staining, showing that staggering of the proliferating chondrocyte is disrupted, and the hypertrophic zone is shorter in the mutant mice. (D) Immunohistochemistry for type X collagen highlights the reduced hypertrophic zone in mutant mice (*Rosa26^{mIfitm5/+};Prx1-Cre/-*, bottom) at age 2 weeks (right panel: insert magnified), and a summary of hypertrophic zone length measurements (t-test, n=3 per group, *p=0.016). RZ= resting zone, PZ= proliferative zone, HZ= hypertrophic zone. Scale bar = 200 um.

1 **Figure 4A-B**






Fig. 4: Conditional expression of the mutant *Ifitm5* allele results in increased periosteal skeletal progenitors population in *Rosa26^{mIfitm5/+};Prx1-Cre* mice. (A) Flow cytometry analysis of skeletal progenitor markers in cells isolated from the periosteum. (B) A significant increase in CD105⁺CD140a⁺ population in *Rosa26^{mIfitm5};Prx1-Cre* mutant mice was shown in the periosteum, but not in the bone marrow (t-test, n=6 per group for periosteal cells, *p=0.015; n=4-6 per group for bone marrow cells, ns=not significant).


1 **Figure 5A-B**

2



3

4




5

6

7

1 **Figure 5C**

2



13 **Fig. 5: Conditional expression of the mutant *Ifitm5* allele in *Rosa26^{mIfitm5/+};Prx1-Cre* mice**
 14 **leads to progressive cartilage overgrowth and abnormal development of the ossification**
 15 **centers. (A) Skeletal preparations of 3-week-old *Rosa26^{mIfitm5/+};Prx1-Cre/-* mutant and littermate**
 16 **controls, showing skeletal deformities including shortening and bowing of the femur and tibia,**
 17 **and partially mineralized cartilage overgrowth at the knee and ankle (thin and thick black arrows,**
 18 **respectively). (B) Skeletal radiographs at age 2 months demonstrating short and gracile long**
 19 **bones (red asterisk) with ossification around the knee and ankle (thin and thick white arrows,**
 20 **respectively). Magnified inserts on the right demonstrate sclerotic lines at the femur metaphysis**
 21 **(black arrows). (C) Representative histology images of proximal tibia of control (left panel) and**
 22 **mutant (*Rosa26^{mIfitm5/+};Prx1-Cre/-*, right panel) mice at age 2 months, showing cartilage**
 23 **overgrowth and disruption of the endochondral ossification (red asterisk). Staining with**
 24 **Hematoxylin & Eosin. Scale bar = 2 mm.**

Figure 6A-D




Fig. 6: Activation of ERK signaling contributes to the abnormal skeletal development in OI type V. (A) RPPA in transgenic *Ifitm5^{c.-14C>T}* mouse model. Ratio of phosphorylated ERK to total ERK RPPA signal intensity is increased in calvaria protein extract from mice overexpressing mutant *Ifitm5* (MUT Tg), as compared to mice overexpressing wild type *Ifitm5* (WT Tg), and non-transgenic (NT) littermates (n=8 per group, one-way ANOVA with Tukey's post-hoc tests, all comparisons to Mut Tg group, **p<0.001). (B) Western blot of representative RPPA samples for phosphorylated ERK (p-ERK) and total ERK (t-ERK) in transgenic *Ifitm5^{c.-14C>T}* mouse model. (C) A representative image showing abnormal morphology (abnormal craniofacial development and tail kinking) of embryos injected with mutant *IFITM5* mRNA (MUT *IFITM5*, lower panel) at 5 days post fertilization, compared to normal development of control zebrafish larvae (WT *IFITM5*, upper panel). Surviving larvae were fixed at 5 days post fertilization and stained with Alcian Blue. (D) Left panel: The proportion of *IFITM5* mutant zebrafish that demonstrated dysmorphology (34%) was significantly greater compared to WT and mCherry controls (5-10%, chi-squared test, n=113-116 per group, *p<0.001); Right panel: Treatment with the ERK inhibitor PD325901 (0.2 uM) partially rescued the abnormal development in *IFITM5* mutant zebrafish. The proportion of *IFITM5* mutant zebrafish with typical development increased by 18% at 5 dpf (chi-squared test, n=97 in treatment group and 87 in vehicle group, *p<0.05).

Figure 7A-C






Fig. 7: Expression of the mutant *Ifitm5* allele leads to altered spatio-temporal expression of SOX9. (A) RPPA in transgenic *Ifitm5^{c.-14C>T}* mouse model. SOX9 RPPA signal intensity is increased in calvaria protein extract from mice overexpressing mutant *Ifitm5* (MUT Tg), as compared to mice overexpressing wild type *Ifitm5* (WT Tg), and non-transgenic (NT) littermates (n=8 per group, one-way ANOVA with Tukey's post-hoc tests, all comparisons to Mut Tg group, **p<0.001). (B) Western blot for SOX9 in representative RPPA samples. (C) Representative immunohistochemistry images of proximal tibia of control (top) and mutant (*Rosa26^{mlf5/+}; Prx1-Cre/-*, bottom) mice at age 2 weeks, showing increased intensity and altered distribution of SOX9-positive cells in the growth plate. In the mutant mice, SOX9-positive cells are seen throughout the growth plate including the hypertrophic zone (which is reduced compared to littermate controls). Right panel: magnification of insert. RZ= resting zone, PZ= proliferative zone, HZ= hypertrophic zone. Scale bar = 200 um.

1 **Figure 8A-B**





15



30

1 **Figure 8C-D**



1 **Figure 8E**






Fig. 8: Abnormal skeletal development in *Rosa26^{mIfitm5};Acan-Cre ERT2* mice is partially rescued by *Sox9* deletion. (A-C) Histology sections of

Rosa26^{mIfitm5/+};Acan-Cre ERT2 mice, showing disrupted growth plate architecture caused by post-natal activation of mutant *Ifitm5* in chondrocytes (left panel, bottom), while *Sox9* deletion (right panel, bottom) rescued the growth plate structure. Hematoxylin & Eosin (A) and immunohistochemistry for SOX9 (B) and type X collagen (C), Scale bar=200 uM. (D) Growth delay in *Rosa26^{mIfitm5/+};Acan-Cre ERT2* mutant mice (middle), compared to wild type (left) and partial rescue by *Sox9* deletion (right). (E) Micro-CT analysis of femur length (left) and BV/TV (right) in *Rosa26^{mIfitm5/+};Acan-Cre ERT2* mice, showing low bone mass in mutant mice, and partial rescue by *Sox9* deletion (one-way ANOVA, n=6-8 per group, ***p=0.0005). For all experiments shown, *Cre* recombinase was activated by intraperitoneal tamoxifen injections (10 mg/kg/dose) at P.10-15 and samples collected at age 5 weeks.

Figure 9A-B




B



1 **Figure 9C**

2
3 **C**



4

5

6

7

8

9

10

11

12


13

14

15

16

Figure 9D



1 **Fig. 9: Expression of the mutant *Ifitm5* allele leads to altered skeletal stem cell**
2 **differentiation and enhanced chondrogenesis.** (A-B) Lineage tracing of chondrocytes co-
3 expressing mutant *Ifitm5* and Ai9 reporter in *Rosa26^{mIfitm5/Ai9};Acan-Cre ERT2* mice. Tamoxifen
4 induction was performed at postnatal day 10 and bones were collected after 3 weeks (age 5
5 weeks). Representative images of proximal tibia (A) and tibia diaphyseal area (B). Decreased
6 fraction of Ai9+ cells migrated to the bone diaphysis in mutant animals compared to littermate
7 controls (n=3 per genotype, n=2-3 fields counted per sample at x20 magnification, t test
8 *p=0.03). (C) RNA sequencing in total femur cDNA from *Rosa26^{mIfitm5/+};Acan-Cre ERT2* mice
9 (n=3 per genotype) showed enrichment for chondrogenic gene expression in the mutant samples
10 by GO term analysis. (D) Heat map of focused differential gene expression analysis from RNA
11 sequencing, showing upregulation of chondrogenic gene markers and decreased expression of
12 osteogenic markers in the mutants compared to control group.